{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+Blood&page=18", "query": { "intervention": "Peripheral Blood", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 20690, "total_pages": 2069, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+Blood&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+Blood&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T11:30:50.993Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04539275", "title": "VA CoronavirUs Research and Efficacy Studies-1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Convalescent Plasma", "type": "DRUG" }, { "name": "Masked Saline Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2020-11-16", "completion_date": "2021-09-30", "has_results": true, "last_update_posted_date": "2022-09-23", "last_synced_at": "2026-11-13T11:30:50.993Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04539275" }, { "nct_id": "NCT01038557", "title": "Frozen Red Blood Cell Transfusions in Trauma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Blood Loss", "Anemia", "Trauma" ], "interventions": [ { "name": "RBC units", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "15 Years to 100 Years" }, "enrollment_count": 254, "start_date": "2010-01", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2020-01-28", "last_synced_at": "2026-11-13T11:30:50.993Z", "location_count": 5, "location_summary": "Cincinnati, Ohio • Portland, Oregon • Dallas, Texas + 2 more", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01038557" }, { "nct_id": "NCT00455312", "title": "Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Dyskeratosis Congenita", "Aplastic Anemia" ], "interventions": [ { "name": "Campath 1H", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "PROCEDURE" }, { "name": "Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "antithymocyte globulin", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 36, "start_date": "2007-08", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-11-13T11:30:50.993Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00455312" }, { "nct_id": "NCT03153319", "title": "Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mucopolysaccharidosis I", "Mucopolysaccharidosis II", "Mucopolysaccharidosis VI" ], "interventions": [ { "name": "Adalimumab Injection [Humira]", "type": "DRUG" }, { "name": "Saline Solution for Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": null, "sex": "ALL", "summary": "5 Years and older" }, "enrollment_count": 14, "start_date": "2017-06-05", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-11-13T11:30:50.993Z", "location_count": 1, "location_summary": "Torrance, California", "locations": [ { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03153319" }, { "nct_id": "NCT01206530", "title": "FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Rectal Cancer", "Colon Cancer", "Metastasis", "Adenocarcinoma" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2010-09", "completion_date": "2017-09", "has_results": false, "last_update_posted_date": "2019-04-18", "last_synced_at": "2026-11-13T11:30:50.993Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01206530" }, { "nct_id": "NCT00113464", "title": "Developing Newborn Screening for Infants With Primary Immunodeficiency", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Immune System Diseases" ], "interventions": [], "intervention_types": [], "sponsor": "National Human Genome Research Institute (NHGRI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 100, "start_date": "2005-06-02", "completion_date": "2007-04-13", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-11-13T11:30:50.993Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00113464" }, { "nct_id": "NCT02131064", "title": "A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Trastuzumab Emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 444, "start_date": "2014-06-25", "completion_date": "2018-05-29", "has_results": true, "last_update_posted_date": "2019-07-02", "last_synced_at": "2026-11-13T11:30:50.993Z", "location_count": 16, "location_summary": "Fullerton, California • Los Angeles, California • San Luis Obispo, California + 13 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Luis Obispo", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02131064" }, { "nct_id": "NCT01545232", "title": "Pragmatic, Randomized Optimal Platelet and Plasma Ratios", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Trauma" ], "interventions": [ { "name": "1:1:1 Blood Transfusion Ratio", "type": "BIOLOGICAL" }, { "name": "1:1:2 Blood Transfusion Ratio", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 680, "start_date": "2012-08", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2019-02-08", "last_synced_at": "2026-11-13T11:30:50.993Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01545232" }, { "nct_id": "NCT04323098", "title": "Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "valoctocogene roxaparvovec", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BioMarin Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 22, "start_date": "2020-12-08", "completion_date": "2025-05-08", "has_results": true, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-11-13T11:30:50.993Z", "location_count": 3, "location_summary": "Sacramento, California • St Louis, Missouri • Columbus, Ohio", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04323098" }, { "nct_id": "NCT00141037", "title": "Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Diseases", "Kidney Transplantation", "Kidney Transplant", "Renal Transplantation", "Renal Transplant" ], "interventions": [ { "name": "Daclizumab", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Ganciclovir", "type": "DRUG" }, { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Trimethoprim and sulfamethoxazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 130, "start_date": "2004-03", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2016-11-29", "last_synced_at": "2026-11-13T11:30:50.993Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00141037" } ] }